ClinicalTrials.gg
RecruitingNCT07538583Updated Sep 28, 2026

Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome

A Phase 2/3 interventional study of QRX003 in Netherton Syndrome, sponsored by Quoin Pharmaceuticals. Recruiting at 8 sites in 2 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Quoin Pharmaceuticals · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2026; still recruiting 7 months later.
Updated Sep 28, 2026First site in United KingdomStudy contact changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Netherton Syndrome with a site in United States — 4 open to participants now, 6 under way, 4 of them phase 3. Netherton Syndrome · United States.

Planned enrollment
8th of 12
16 · median 20
Started
2026
the only one that year
Phase 2/3
5 of 14
3 open now
Registered
14th of 14
by date
Lead sponsor
4 of 14
Quoin Pharmaceuticals

Among the 14 studies in Netherton Syndrome with a site in United States, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 2/3, and was the 14th registered.

Netherton Syndrome

22 studies on the registry are indexed under Netherton Syndrome; 5 are open to participants now.

Browse Netherton Syndrome studies →

Open to participants now

4 of the 14 studies in Netherton Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 4 Netherton Syndrome studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 4 take children under 18; none take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Netherton Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label study to evaluate the safety, tolerability, and efficacy of 4% QRX003 lotion applied twice daily (BID) for 12 weeks to Netherton syndrome (NS) diseased skin in all affected areas of the body excluding the scalp (the Treatment Area), totaling approximately 50% Body Surface Area (BSA) or more.

03

Conditions studied

  • Netherton Syndrome

Browse trials for

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant is male or female and at least 4 years of age.
  2. Participant has provided written /assent. Based on the participant's age and local regulations , a participant under legal age of consent must provide written informed assent and be accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian must provide informed consent for the participant. If a participant reaches the age at which consent is required by local regulations during the study, the participant must provide written informed consent at that time to continue study participation.
  3. Female participants must either not have experienced menarche, be , or be surgically sterile , or use a highly effective method of , for the duration of the study and for 3 months following EOT. Women of (WOCBP) must have a negative urine pregnancy test (UPT) at Visit 1/Screening and Visit 2/Baseline. Males must use a condom in addition to having their female partner use a highly effective method of birth control.
  4. Participant has a genetically confirmed diagnosis of NS prior to Visit 2/Baseline. Participants without existing results must undergo genetic testing at Visit 1/Screening, which must confirm the diagnosis of NS in order for the participants to be enrolled in the study.

Exclusion criteria

Exclusion Criteria:

  1. Participant is pregnant, lactating, or is planning to become pregnant during the study.
  2. Participant has active cancer of any type excluding melanoma skin cancer outside of the Treatment Area.
  3. Participant has diabetes of any type, except non-insulin dependent diabetes mellitus that is reasonably controlled, in the opinion of the investigator.
  4. Participant has evidence of active infection during Screening, or serious infection within 30 days prior to Visit 2/Baseline.
  5. Participant has known , or C virus, or active or latent tuberculosis.
  6. Participant has ongoing or recent history of any other uncontrolled and/or systemic disease or condition which, in the opinion of the investigator, should exclude participation in the study.
  7. Participant has used ultraviolet phototherapy within the Treatment Area within 4 weeks prior to Visit 2/Baseline.
  8. Participant has used systemic non-biologics prescription treatment for NS or that in the opinion of the investigator may affect the participant's NS (examples include, but are not limited to antibiotics, retinoids, etc.) within 4 weeks prior to Visit 2/Baseline.
  9. Participant has used systemic biologic therapy for NS or that in the opinion of the investigator may affect the participant's NS within 5 half-lives of the biologic therapy prior to Visit 2/Baseline. Published or documented half-life of the product provided by the commercial supplier or Sponsor should be used to establish this value.
  10. Participant has used topical prescription treatments, including (examples include, but are not limited to keratolytics, steroids, retinoids, etc.) in the Treatment Area within 2 weeks prior to Visit 2/Baseline.
  11. Participant has used any topical bland moisturizers/emollients in the Treatment Area within 24 hours prior to Visit 2/Baseline.
  12. Participant is currently enrolled in an drug, biologic, or device study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    QRX003 lotion, 4% BID

    Subjects will apply test article twice daily (BID) for 12 weeks

    Drug: QRX003

Interventions

  • DrugQRX003

    Serine Protease Inhibitor

06

What researchers measure

Primary outcomes

  1. Proportion of subjects with 1-point reduction on IGA

    The IGA (Investigator Global Assessment) is a 5-point scale used to assess the overall severity of a Subject's NS condition.

    Time frame: Week 12

Secondary outcomes

  1. Proportion of subjects with 2-point improvement on the WI-NRS

    Subjects will rate their itch intensity using the 11-point Worst-Itch-Numeric Rating Scale (WI-NRS)

    Time frame: Week 12

  2. PGI-C Score

    Patient (or Caregiver) Global Impression of Change (PGI-C) is a 7-point, self-assessed scale measuring the patient's (or caregiver's) improvement of their NS condition.

    Time frame: Week 12

  3. CGI-C Score

    Clinical Global Impression of Change (PGI-C) is a 7-point scale used by the clinician to assess improvement of the NS condition.

    Time frame: Week 12

07

Study locations

7 of 8 sites recruiting
  • Center for Dermatology Clinical Research
    Fremont, California 94538, United States
    Recruiting
  • Yale University School of Medicine
    New Haven, Connecticut 06520, United States
    Not yet recruiting
  • Dawes Fretzin Clinical Reseacrh Group
    Indianapolis, Indiana 46250, United States
    Recruiting
  • Beacon Clinical Research
    Quincy, Massachusetts 02169, United States
    Recruiting
  • Texas Dermatology and Laser Specialists
    San Antonio, Texas 78218, United States
    Recruiting
  • Great Ormond Street Hospital, NIHR - Clinical Research
    London, England WC1N 3JH, United Kingdom
    Recruiting
  • Walsall Manor Hospital, Research & Development
    Walsall, West Midlands WS2 9PS, United Kingdom
    Recruiting
  • Guy's Hospital, Skin Therapy Research Unit
    London, SE1 9RT, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2026 (actual). Primary completion is estimated for Jan 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2026
First posted
Apr 20, 2026
StartActual
Mar 19, 2026
Primary completionEst.
Jan 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added — first site in United Kingdom
Show 3 added (3 United Kingdom)
  • Great Ormond Street Hospital, NIHR - Clinical Research · London, United Kingdom
  • Walsall Manor Hospital, Research & Development · Walsall, United Kingdom
  • Guy's Hospital, Skin Therapy Research Unit · London, United Kingdom
Sep 28, 2026
Contact
Study contact changed: o•••@therapeuticsinc.com · •••1800→l•••@therapeuticsinc.com · •••1800. See the current contact
Sep 28, 2026
Site contacts
Changed at 5 sites. See the sites
Show 5 sites
  • Center for Dermatology Clinical Research · Fremont, United StatesContact removed o•••@therapeuticsinc.com · •••1800
  • Yale University School of Medicine · New Haven, United StatesContact removed o•••@therapeuticsinc.com · •••1800
  • Dawes Fretzin Clinical Reseacrh Group · Indianapolis, United StatesContact removed o•••@therapeuticsinc.com · •••1800
  • Beacon Clinical Research · Quincy, United StatesContact removed o•••@therapeuticsinc.com · •••1800
  • Texas Dermatology and Laser Specialists · San Antonio, United StatesContact removed o•••@therapeuticsinc.com · •••1800
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    3 sites added — first site in United Kingdom
    Show 3 added (3 United Kingdom)
    • Great Ormond Street Hospital, NIHR - Clinical Research · London, United Kingdom
    • Walsall Manor Hospital, Research & Development · Walsall, United Kingdom
    • Guy's Hospital, Skin Therapy Research Unit · London, United Kingdom
    Contact Study contact changed: o•••@therapeuticsinc.com · •••1800→l•••@therapeuticsinc.com · •••1800. See the current contact
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Center for Dermatology Clinical Research · Fremont, United StatesContact removed o•••@therapeuticsinc.com · •••1800
    • Yale University School of Medicine · New Haven, United StatesContact removed o•••@therapeuticsinc.com · •••1800
    • Dawes Fretzin Clinical Reseacrh Group · Indianapolis, United StatesContact removed o•••@therapeuticsinc.com · •••1800
    • Beacon Clinical Research · Quincy, United StatesContact removed o•••@therapeuticsinc.com · •••1800
    • Texas Dermatology and Laser Specialists · San Antonio, United StatesContact removed o•••@therapeuticsinc.com · •••1800

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07538583
Lead sponsor
Quoin Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 20, 2026
Start date
Mar 19, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 28, 2026

Study contacts

TI Clinical Research
Contact
clinicalresearch@therapeuticsinc.com
858-571-1800 ext. 147
Lisa Duarte
Contact
lduarte@therapeuticsinc.com
858-571-1800 ext. 185

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: QRX003

Start the discussion